Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
Pre-Market: $482.00 -4.62 (-0.95%) 9:24 AM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
Pre-Market: $482.00 -4.62 (-0.95%) 9:24 AM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
Bio-Rad (BIO) Banks on Blood Typing Market Amid Margin Woes
by Zacks Equity Research
Bio-Rad (BIO) actively expands portfolio for blood typing market; declining gross margin a concern.
Becton, Dickinson Global Foothold Strong, Recalls Rampant
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid global foothold in Q3; foreign exchange headwinds raise concern.
Has Intuitive Surgical (ISRG) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ISRG) Outperforming Other Medical Stocks This Year?
STERIS (STE) Q1 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
STERIS (STE) continues to gain from strength in all business segments in Q1.
Allscripts Sunrise Picked by UK's Maidstone and Tunbridge Wells
by Zacks Equity Research
Allscripts' (MDRX) Sunrise platform witnesses a suite of developments, fortifying the company's global foothold.
Haemonetics (HAE) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Haemonetics' (HAE) year-over-year growth is backed by the solid execution of its multi-year turnaround strategy.
OPKO Health (OPK) Earnings & Revenues Beat Estimates in Q2
by Zacks Equity Research
OPKO Health (OPK) gains from robust demand for its flagship RAYALDEE; declining segmental revenues raise concern.
Wright Medical (WMGI) Beats on Q2 Earnings, Raises '18 View
by Zacks Equity Research
Growth in the upper and lower extremity segments drives Wright Medical's (WMGI) Q2 results.
Bio-Rad (BIO) Tops Earnings and Revenue Estimates in Q2
by Zacks Equity Research
Bio-Rad's (BIO) solid growth in North America, China and Asia Pacific reflects strong international foothold in Q2.
CVS Health's (CVS) Q2 Earnings Beat Estimate, Margins Up
by Zacks Equity Research
CVS Health (CVS) reports strong Pharmacy Services revenues, benefiting from the upside in the specialty services. Year-over-year Retail/LTC comparisons are also encouraging.
BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
A shift in BioScrip's (BIOS) strategy and the impact of implementing ASC 606 induce a Q2 earnings miss for the company. However, its progress with the new multi-faceted CORE plan is a positive.
Allscripts Gains From Strong Results in Q2, Competition Rife
by Zacks Equity Research
Allscripts (MDRX) continues to gain from solid Q2 results and EHR developments; a competitive industry is a concern.
Penumbra (PEN) Q2 Earnings & Revenues Top Estimates, View Up
by Zacks Equity Research
Penumbra (PEN) benefits from strong growth across all geographies and product lines in Q2.
Inogen (INGN) Beats on Q2 Earnings, Lifts '18 Sales Guidance
by Zacks Equity Research
Inogen (INGN) puts up solid segmental show in Q2; international sales surge.
Surmodics (SRDX) Beats Q3 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Surmodics' (SRDX) third-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.
Teleflex (TFX) Q2 Earnings Top, Sales Lag, '18 View Bearish
by Zacks Equity Research
Teleflex (TFX) rides high on a strong year-over-year revenue improvement, banking on balanced segmental growth and wide geographical expansion.
DENTSPLY (XRAY) Beats on Q2 Earnings, Lowers 2018 Guidance
by Zacks Equity Research
DENTSPLY (XRAY) gains from solid year-over-year international revenue growth in Q2; high impairment charges in the quarter mars results.
Luminex (LMNX) Misses on Earnings in Q2, Margins Contract
by Zacks Equity Research
Luminex (LMNX) gains on ARIES and VERIGENE platforms in Q2; a solid guidance encourages.
Insulet (PODD) Q2 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
We are encouraged by the year-over-year improvement in Insulet's (PODD) results on solid uptake of Omnipod system in the United States in Q2.
Henry Schein's (HSIC) Q2 Earnings Beat, '18 EPS View Up
by Zacks Equity Research
All four of Henry Schein's (HSIC) operating segments recorded strong year-over-year growth in Q2.
Allscripts (MDRX) Q2 Earnings In Line, Revenues Top Estimates
by Zacks Equity Research
Allscripts (MDRX) gains from solid segmental performance in Q2; a decline in bookings discourages.
Cardinal Health (CAH) Surpasses Earnings Estimates in Q4
by Zacks Equity Research
Cardinal Health (CAH) witnesses strong Q4, owing to strong sales at Pharmaceutical and the Medical segments. It provides an impressive FY19 view.
Bruker (BRKR) Q2 Earnings Meet Estimates, Margins Expand
by Zacks Equity Research
Bruker's (BRKR) strategic M&A activity is consistently raising investors' hopes. Further, the company's current focus on product development through higher R&D is an upside.
Quality Systems (QSII) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Quality Systems (QSII) gains from solid bookings in Q2; growing pipeline encourages.
Cerner (CERN) Beats Q2 Earnings Estimates, Bookings Rise Y/Y
by Zacks Equity Research
Cerner (CERN) gains from solid bookings growth in Q2; developments in the EHR front are promising.